4P-Pharma is a team of drug developers driven by the shared goal of translating disruptive innovations into breakthrough curative therapies to answer patient’s unmet needs.

Drug development is a long, risky and expensive process. It has become extremely difficult to find pharmaceutical companies willing to invest in technologies at early stage of development. As a result, the number of new drugs entering the development pipeline is dangerously drying up, and a lot of early stage technologies are lost despite their great potential.

To face this challenge, Revital Rattenbach founded 4P-Pharma in 2014 to build a bridge between academic research and industrial development through strong partnerships with the aim to accelerate drug development and reduce the drugs pipeline attrition rate.

We detect the most promising early-stage projects and perform in-house technological due-diligence applying stringent criteria. We gather all the relevant actors from the clinic, drug development, finance and business fields to move technologies through developmental decision, building bridges to bring innovations to clinical phases and closer to patients’ bedside.

  • August 2014

    4P-Pharma foundation

    Incubation at Eurasanté bio-incubator and Pasteur Institute of Lille

  • 2015

    First partnerships with SATTs

  • 2016

    M comme Mutuelle entered in our capital

  • 2017

    Partnership with the SATT Lutech and the Pr. Berenbaum on 4P-004

    First-in-man of 4P-003, a proprietary molecule

  • 2018

    Member of the Bpifrance Excellence business network

  • 2019

    First partnerships with drug discovery biotech companies using AI and in silico modelling

  • 2020

    Incorporation of 4Moving Biotech, our 4P-004 centered company,

    and 4Living Biotech, our 4P-021 centered company.